Noriyuki Kasahara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5300775/publications.pdf

Version: 2024-02-01

42	1,680	279798 23	315739 38
papers	citations	h-index	g-index

43	43	43	1543
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
2	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 2018, 20, 1383-1392.	1.2	135
3	Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression. Molecular Therapy, 2012, 20, 1689-1698.	8.2	119
4	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology, 2012, 14, 145-159.	1.2	117
5	Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma. Molecular Therapy, 2005, 12, 842-851.	8.2	105
6	Highly Efficient and Tumor-Restricted Gene Transfer to Malignant Gliomas by Replication-Competent Retroviral Vectors. Human Gene Therapy, 2003, 14, 117-127.	2.7	82
7	A Uniquely Stable Replication-Competent Retrovirus Vector Achieves Efficient Gene Deliveryin Vitroand in Solid Tumors. Human Gene Therapy, 2001, 12, 921-932.	2.7	81
8	Replication-competent retrovirus vectors for cancer gene therapy. Frontiers in Bioscience - Landmark, 2008, 13, 3083.	3.0	68
9	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro-Oncology, 2017, 19, 930-939.	1.2	65
10	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
11	Therapeutic Efficacy of Replication-Competent Retrovirus Vectorâ€"Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model. Cancer Research, 2007, 67, 5345-5353.	0.9	56
12	Intravenous Administration of Retroviral Replicating Vector, Toca 511, Demonstrates Therapeutic Efficacy in Orthotopic Immune-Competent Mouse Glioma Model. Human Gene Therapy, 2015, 26, 82-93.	2.7	55
13	Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-Î³ after differentiation of glioblastoma by human natural killer cells. Cancer Immunology, Immunotherapy, 2016, 65, 1085-1097.	4.2	54
14	Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector. Journal of Virology, 2002, 76, 12783-12791.	3.4	51
15	Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors. Current Gene Therapy, 2005, 5, 655-667.	2.0	50
16	Retroviral replicating vectorâ€"mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro-Oncology, 2017, 19, 918-929.	1.2	41
17	Optimization of enzymeâ€"substrate pairing for bioluminescence imaging of gene transfer using Renilla and Gaussia luciferases. Journal of Gene Medicine, 2010, 12, 528-537.	2.8	31
18	Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Therapy, 2014, 21, 405-410.	4.6	30

#	Article	IF	Citations
19	Tumor-Selective Gene Expression in a Hepatic Metastasis Model after Locoregional Delivery of a Replication-Competent Retrovirus Vector. Clinical Cancer Research, 2006, 12, 7108-7116.	7.0	29
20	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. Clinical Cancer Research, 2007, 13, 4511-4518.	7.0	29
21	Short Conserved Sequences of HIV-1 Are Highly Immunogenic and Shift Immunodominance. Journal of Virology, 2015, 89, 1195-1204.	3.4	27
22	A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Molecular Therapy - Oncolytics, 2018, 8, 14-26.	4.4	26
23	Selectively Replicating Adenoviruses for Oncolytic Therapy. Current Cancer Drug Targets, 2001, 1, 85-107.	1.6	24
24	Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?. Journal of Immunology Research, 2017, 2017, 1-14.	2.2	20
25	A CK1Î± Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. Clinical Cancer Research, 2019, 25, 1379-1388.	7.0	20
26	Retroviral Replicating Vectors in Cancer. Methods in Enzymology, 2012, 507, 199-228.	1.0	19
27	Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. Journal of Neuro-Oncology, 2017, 134, 29-40.	2.9	19
28	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy, 2018, 25, 184-195.	4.6	14
29	Retrovirus-Mediated Gene Transfer to Tumors: Utilizing the Replicative Power of Viruses to Achieve Highly Efficient Tumor Transduction In Vivo. , 2004, 246, 499-526.		13
30	Dual-vector prodrug activator gene therapy using retroviral replicating vectors. Cancer Gene Therapy, 2019, 26, 128-135.	4.6	13
31	Factors in the Selection of Surface Disinfectants for Use in a Laboratory Animal Setting. Journal of the American Association for Laboratory Animal Science, 2016, 55, 175-88.	1.2	13
32	Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opinion on Biological Therapy, 2021, 21, 1199-1214.	3.1	11
33	Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neuro-Oncology Practice, 2020, 7, 465-476.	1.6	10
34	Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. International Journal of Molecular Sciences, 2020, 21, 1433.	4.1	10
35	Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors. Cancer Gene Therapy, 2019, 26, 41-47.	4.6	8
36	Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. Journal of Neuro-Oncology, 2021, 152, 1-13.	2.9	7

#	Article	IF	Citations
37	Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model. Oncology Reports, 2015, 34, 633-638.	2.6	4
38	Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene. Human Gene Therapy Methods, 2016, 27, 59-70.	2.1	3
39	EXTH-33. RETROVIRAL REPLICATING VECTORS PSEUDOTYPED WITH GIBBON APE LEUKEMIA VIRUS ENVELOPE FOR PRODRUG ACTIVATOR GENE THERAPY IN PRECLINICAL GLIOMA MODELS. Neuro-Oncology, 2021, 23, vi170-vi170.	1.2	1
40	THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii472-iii472.	1.2	0
41	EXTH-65. INSERTION OF MICRORNA TARGET SEQUENCES INTO RETROVIRAL REPLICATING VECTORS EFFECTIVELY RESTRICTS TRANSGENE EXPRESSION AND VIRAL REPLICATION IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS. Neuro-Oncology, 2021, 23, vi178-vi178.	1.2	0
42	EXTH-13. LOCAL DELIVERY OF AN IL-15 SUPERAGONIST USING A REPLICATING RETROVIRUS SIGNIFICANTLY IMPROVES SURVIVAL AND LYMPHOCYTE INFILTRATION IN POORLY IMMUNOGENIC MURINE GLIOBLASTOMA MODELS. Neuro-Oncology, 2021, 23, vi166-vi166.	1.2	0